Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference

PR Newswire September 6, 2017

Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results

PR Newswire August 2, 2017

Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call

Accesswire August 2, 2017

Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia

PR Newswire July 21, 2017

Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017

PR Newswire July 17, 2017

Technical Insights on Biotech Stocks -- Curis, OvaScience, Regulus Therapeutics, and Vanda Pharma

PR Newswire July 12, 2017

Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences

PR Newswire June 5, 2017

Research Reports Initiation on Biotech Stocks -- Corcept Therapeutics, Curis, OvaScience, and Vanda Pharma

PR Newswire May 30, 2017

Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results

PR Newswire May 2, 2017

Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call

Accesswire May 2, 2017

Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference

PR Newswire May 1, 2017

Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017

PR Newswire April 13, 2017

Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors

PR Newswire March 29, 2017

How These Biotech Stocks are Faring? -- Corbus Pharma, Advaxis, Vanda Pharma, and Nivalis Therapeutics

PR Newswire March 7, 2017

Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences

PR Newswire March 6, 2017

Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results

PR Newswire February 15, 2017

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  February 8, 2017

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017

PR Newswire January 19, 2017

Research Reports Coverage on Biotech Stocks -- Cara Therapeutics, Heat Biologics, Vanda Pharma, and Opexa Therapeutics

PR Newswire January 10, 2017

Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance

PR Newswire January 9, 2017